Tebentafusp, the first FDA-approved treatment option for patients with unresectable or metastatic uveal melanoma, may cause mild cytokine release syndrome, an expert explains.
Paul Nathan, PhD
Advertisement
Articles by Paul Nathan, PhD
Advertisement
Latest Updated Articles
Newly Approved Tebentafusp Requires Up-Front Active Toxicity Management in MelanomaPublished: February 14th 2022 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Race Identified as Prognostic Indicator in Black Patients With AML
2
Families of Children With ALL Face Extreme Financial Toxicity
3
Fixed-Duration Venetoclax Regimens Yield Noninferior CLL PFS to Ibrutinib
4
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma
5
